In part due to research by two University of Michigan researchers, a form of leukemia can be treated more easily through an FDA-approved drug.

Arsenic and old ideas once used to treat a deadly cancer are being overhauled by enormous strides in new treatments, turning ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global, commercial ...

Compared with white patients, Black patients with an aggressive form of leukemia--called acute myeloid leukemia (AML)--were ...

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the publication of the Precision-T Phase 3 study ...

Detailed price information for Terns Pharmaceuticals Inc (TERN-Q) from The Globe and Mail including charting and trades.

In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in the conditions of 63 enrolled patients ...

I’m a 63-year-old male diagnosed with chronic myelogenous leukemia, Type 2 diabetes and coronary heart disease. I am 5 feet, 11 inches and weigh 240 pounds. I ...

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a third of the patients achieved deep molecular remission. Overall, Haddad ...

The latest update is out from Enliven Therapeutics ( (ELVN) ).

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.